GE HealthCare just dropped an AI-powered ultrasound that’s faster, sharper, and quietly aiming to reboot cardiac imaging.

This week’s lineup features more than a few overlooked names doing big things: from defense upgrades to solar expansions and financials flying under the radar, there’s no shortage of undervalued plays gaining traction.

Don’t Let These Undervalued Stocks Slip Through Your Fingers!

We now send our favorite value picks via text, too, so you’ll get the same actionable news without having to open your inbox.

👉 Click here to get stock picks by text and uncover the best value opportunities!

Healthcare

GE HealthCare (NASDAQ: GEHC)  is turning heads with its Vivid Pioneer, the company’s sleekest, AI-powered cardiovascular ultrasound yet.

With CE Mark and FDA 510(k) clearances in the rearview, this platform promises sharper imaging, faster workflows, and automation that slashes scan times by a jaw-dropping 300%, basically giving cardiologists a superhero upgrade.

The hype is real: GEHC is gunning for its slice of the $187B AI-in-healthcare pie, where speed, precision, and efficiency are king.

With Auto Doppler, 4D Auto LHQ, and ergonomic features that make long shifts less brutal, the system could become the go-to choice in echo labs, cath labs, and even bedside settings, while generating recurring revenue from probes and service contracts.

Shares shrugged on launch day at $73.73 and are down 5.7% YTD despite a 10% S&P gain.

But don’t sleep on this one. Recent earnings surprises have averaged over 16%, and as AI-driven imaging ramps up globally, GEHC could go from “meh” to must-own.

At a $33.6B market cap, trading below some fair value estimates that suggest 15% upside, the Vivid Pioneer launch is staking its claim in the future of heart care, even with tariffs and supply chain headaches lingering.

Industrials

Leidos Holdings, Inc. (NYSE: LDOS)  is back in the headlines after RBC Capital bumped its rating to Outperform from Sector Perform and slapped a $210 price target on the table.

The rationale? CEO Tom Bell’s overhaul seems to be paying off, with defense and health units flexing some serious muscle.

RBC is betting on continued earnings beats, upward revisions, and even M&A optionality, basically leaving room for some juicy upside.

The upgrade follows a Q2 showing that topped expectations, with full-year adjusted EPS guidance lifted to $11.15–$11.45 and revenue forecasts tightened to $17 billion–$ 17.25 billion.

The Health & Civil unit, buoyed by elevated veterans exam volumes, remains the secret sauce driving margin gains.

Shares may have dipped 1.76% to $177.71 and lurked in four straight sessions of mild gloom, but with institutional investors like JPMorgan quietly scooping up stakes, Leidos is quietly setting the stage for a multi-year re-rating story.

With an $210 price target implying ~18% upside, patience could pay off for anyone playing the long game in defense and health services.

Technology

Zeta Global is back on the radar after Goldman Sachs bumped its price target from $16 to $18 following a 25% revenue surge in Q2 to $308 million, beating estimates by a cool $12 million.

Net losses narrowed to $12.8 million, down from $28 million a year ago, suggesting that operational tweaks are actually taking hold.

Despite the good news, Goldman stayed neutral, citing ongoing capital needs and a bit of shareholder uncertainty. Translation: growth is real, but cash flow clarity is still playing hard to get.

Zeta sits at the sweet spot where AI-powered marketing meets enterprise software, helping brands charm and stick to customers.

With a 12% upside baked in at current levels, the stock is quietly positioning itself as one to watch for patient investors who like growth stories without the hype circus.​

Warner Bros. Discovery is quietly setting the stage for long-term value.

With streaming and studio operations finally finding their footing, and debt-reduction plans underway, WBD could be the turnaround story investors have been waiting for.

Wall Street has taken note, assigning a Moderate Buy consensus and hinting at upside potential as the split with Discovery Global reshapes the balance sheet.

For patient investors, WBD is like a sleeper hit: the buzz hasn’t fully caught up to the story yet, but the fundamentals suggest it’s ready for a sequel.

Carnival is leaving ATAT in its wake. With a forward P/E of 15.6 compared to ATAT’s frothy 25.1, and a PEG ratio less than half its rival’s, Carnival’s valuation looks downright ocean-worthy.

After years of treading water, it’s finally powering ahead with purpose.

What used to be a pandemic punchline is now a full-blown recovery story — minus the drama. Bookings are up, debt’s heading down, and the balance sheet no longer looks like a sinking ship.

This isn’t a moonshot. It’s a cruise ship turning slowly but surely in the right direction.

For value investors tired of chasing overcooked tech, CCL offers a rare combo: rising fundamentals, improving sentiment, and a stock price that still thinks it’s 2020.

BanColombia isn’t showing up on CNBC. It’s not getting memed. And that’s exactly the point.

This thing is a disciplined, profit-churning machine hiding in an emerging-market wrapper.

While everyone else is busy bidding up the same five AI stocks, CIB is quietly compounding, managing risk like a pro, and trading at a discount that would make a coupon clipper blush.  

Add steady earnings estimates and a forward P/E flirting with historical lows, and you’ve got a stock that could quietly reward patient investors. 

If you like your banks boring, your margins healthy, and your upside underappreciated, this is one to stash before the herd catches on.

That's our coverage for today; thanks for reading! Reply to this email with feedback or any value names you'd like us to dig into.

Best Regards,
—Noah Zelvis
Undervalued Edge